Pfizer and the Drugs for Neglected Diseases initiative announced the collaboration Wednesday. The DNDi scientists will screen Pfizer drug candidates to see if they are effective against sleeping sickness -- also called human African trypanosomiasis -- visceral leishmaniasis, and Chagas disease.